Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease

Mitchell, Natalie; Harrison, Nicole; Junga, Zachary; Singla, Manish

doi:10.1093/ibd/izy157

Cited by 32 publications

(36 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pericarditis represents the most frequent cardiovascular EIM in IBD patients (70% of the total number of cardiovascular complications) [15, 16]. Its prevalence is 0.19% among the CD patients and 0.23% among the UC patients [17].…”

Section: Epidemiology Of Cardiovascular Eimmentioning

confidence: 99%

Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies

Bunu

Timofte²,

Ciocoiu

et al. 2019

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) refers to a group of chronic inflammatory diseases that targets mainly the gastrointestinal tract. The clinical presentation of IBD includes both gastrointestinal manifestations and extraintestinal manifestations (EIM). The reported cardiovascular manifestations in IBD patients include pericarditis, myocarditis, venous and arterial thromboembolism, arrhythmias, atrioventricular block, heart failure, endocarditis, valvulopathies, and Takayasu arteritis. The aim of this article is to review the available literature about the possible pathogenic mechanisms and determine preventive measures capable of reducing the incidence and severity of the cardiovascular manifestations. In IBD patients, the incidence of cardiovascular manifestations is low, but higher than that in the general population. Therefore, clinicians should pay attention to any new modification that might indicate cardiovascular involvement in IBD patients, and they should consider chronic inflammatory diseases in patients with cardiac conditions without an evident cause. Considering the role of inflammation in the development of cardiovascular manifestations, the management should include prevention of flares and maintenance of remission for as long as possible. Preventive measures should also include active screening and strict control of the cardiovascular risk factors in all IBD patients.

show abstract

Section: Epidemiology Of Cardiovascular Eimmentioning

confidence: 99%

Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies

Bunu

Timofte²,

Ciocoiu

et al. 2019

Gastroenterology Research and Practice

View full text Add to dashboard Cite

show abstract

“…The effect of ASCVD related mortality in patients with IBD is debatable[ 12 , 23 , 26 - 29 ]. This can be attributed to multiple factors.…”

Section: Ascvd and Ibdmentioning

confidence: 99%

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

Weissman

Sinh

Mehta

et al. 2020

WJGP

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) causes systemic vascular inflammation. The increased risk of venous as well as arterial thromboembolic phenomena in IBD is well established. More recently, a relationship between IBD and atherosclerotic cardiovascular disease (ASCVD) has been postulated. Systemic inflammatory diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have well characterized cardiac pathologies and treatments that focus on prevention of disease associated ASCVD. The impact of chronic inflammation on ASCVD in IBD remains poorly characterized. This manuscript aims to review and summarize the current literature pertaining to IBD and ASCVD with respect to its pathophysiology and impact of medications in order to encourage further research that can improve understanding and help develop clinical recommendations for prevention and management of ASCVD in patients with IBD.

show abstract

“…The effects of these agents on cardiac disease observed in rheumatoid arthritis are summarized in Table 2. Both methotrexate and TNF-α antagonists have been associated with a cardioprotective effect due to suppression of systemic inflammation (Barnabe et al, 2011;Lee et al, 2018;Micha et al, 2011;Roubile et al, 2015). These studies have shown prospectively that biological agents reduce the number of adverse cardiac events while this response was not observed in those patients that ceased biological agents during follow-up (Lee et al, 2018).…”

Section: Effect Of Rheumatoid Arthritis Treatment On Myocardial Funmentioning

confidence: 99%

“…As shown in Table 1, inflammatory bowel disease patients present premature signs of subclinical atherosclerosis (Cappello et al, 2017) and increased risk of ischaemic heart disease (IHD), acute myocardial infarction and heart failure (Aniwan, Pardi, Tremaine, & Loftus, 2018; Feng et al, 2017; Fumery et al, 2014). Additional cardiac manifestations are arrhythmias and pericarditis and myocarditis (Mitchell, Harrison, Junga, & Singla, 2018).…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Chronic inflammatory diseases, myocardial function and cardioprotection

Lazou

Ikonomidis

Barteková

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

The association between chronic inflammatory diseases (CIDs) and increased cardiovascular (CV) risk is well documented and can be a most threatening complication in these patients. However, the pathogenetic mechanisms underlying increased CV risk remain elusive, especially in their cellular and biochemical pathways. Using animal models to understand mechanisms underlying cardiac involvement are limited. Additionally, treatments may influence cardiovascular events through different outcomes. Some drugs used to treat CIDs can negatively affect cardiac function by a direct toxicity, whereas others may protect the myocardium. In the present article, we focus on the cardiac manifestations and risk factors, the pathogenetic mechanisms, and the effect of treatments on myocardial function and cardioprotection for five common worldwide CIDs (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, psoriasis and inflammatory bowel disease). We also give recommendations in order to evaluate common targets between CID and CV disease (CVD) and to design therapies to alleviate CID-related CVD.

show abstract

Heart Under Attack: Cardiac Manifestations of Inflammatory Bowel Disease

Cited by 32 publications

References 64 publications

Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies

Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

Chronic inflammatory diseases, myocardial function and cardioprotection

Contact Info

Product

Resources

About